PETS PetMed Express Inc

PetMed Express, Inc. (NASDAQ: PETS) (“PetMeds” or “Company”), Your Trusted Pet Health Expert™, today announced its financial results for its first quarter ended June 30, 2023. 

Quarterly Highlights

• Net sales for the quarter ended June 30, 2023, were $78.2 million, compared to $70.2 million for the first quarter in the prior year, an increase of 11.5%. 
• PetMeds reported an increase in new customers of 25% year over year for the quarter ended June 30, 2023, representing the third consecutive quarter of new customer growth. This includes new customers from the PetCareRx acquisition.
• Net loss for the quarter ended June 30, 2023 was $(0.9) million, or $(0.04) per diluted share, including $1.1 million of acquisition related costs expensed in the quarter. The quarterly results compare to net income of $2.8 million, or $0.14 diluted earnings per share, for the prior year quarter ended June 30, 2022. 
• Adjusted EBITDA1 of $3.3 million for the current year quarter, compared to Adjusted EBITDA of $6.3 million, for the quarter ended June 30, 2022, a decrease of 47%. The decrease was due to increased gross profit and other income, offset by higher G&A expenses and advertising expenses.
• PetMeds successfully closed on the acquisition of PetCareRx on April 3, 2023 and is including almost a full quarter of results in the consolidated results ended June 30, 2023.

"This quarter's performance is a pivotal step in our Company's transformative path,” said Matt Hulett, CEO and President. “After over two years of declining revenues, we have successfully achieved year-over-year growth in our top line.” Hulett continued, “Not only did revenue increase by 11.5%, year-over-year, but 49% of our total revenue was derived from recurring sources such as our AutoShip subscription and PetPlus membership programs. Our journey towards becoming a leader in comprehensive pet health expertise is showing promising progress. The acquisition of PetCareRx has unlocked tremendous growth opportunities, allowing us to expand our product catalog and capitalize on synergies between the two. "

The Board of Directors declared a quarterly dividend of $0.30 per share on the Company’s common stock.  The dividend will be payable on August 18, 2023, to shareholders of record at the close of business on August 14, 2023.  The declaration and payment of future dividends is discretionary and will be subject to the determination by the Board of Directors.

This afternoon the Company will host a conference call to review the quarter’s financial results. 

Time: 4:30 P.M. Eastern Time, July 31, 2023Public call dial in (877) 407-0789 (toll free) or (201) 689-8562.  Webcast stream link: https://investors.petmeds.com/overview/default.aspx for those who wish to stream the call via webcast.  Replay: Available until August 14, 2023, at 11:59 P.M Eastern Time. To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13740086.

Founded in 1996, PetMeds is Your Trusted Pet Health Expert™, providing prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and through its website at www.petmeds.com.

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023.  The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Qs and its Annual Reports on Form 10-K. 

PETMEDS INVESTOR RELATIONS CONTACTBrian M. Prenoveau, CFAMZ Group561-489-5315investor@petmeds.com 

PETMEDS MEDIA CONTACTMary Eva TredwayButin PRmaryeva@butinpr.com

PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except for per share data)
	June 30,2023			March 31,2023
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	61,534		$	104,086
Accounts receivable, less allowance for doubtful accounts of $38 and $35, respectively		1,894			1,740
Inventories - finished goods		32,324			19,023
Prepaid expenses and other current assets		8,530			4,719
Prepaid income taxes		1,548			1,883
Total current assets		105,830			131,451
Noncurrent assets:
Property and equipment, net		27,207			26,178
Intangible and other assets, net		17,671			5,860
Goodwill		20,735			–
Operating lease right-of-use assets, net		2,024			–
Deferred tax assets, net		7,270			628
Total noncurrent assets		74,907			32,666
Total assets	$	180,737		$	164,117
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	40,037		$	25,208
Accrued expenses and other current liabilities		13,240			11,289
Current lease liabilities		799			–
Deferred revenue		3,246			–
Total current liabilities		57,322			36,497
Long-term lease liabilities		1,268			–
Other long-term liabilities		3,825			3,825
Total liabilities		62,415			40,322
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share		9			9
Common stock, $0.001 par value, 40,000 shares authorized; 21,170 and 21,084 shares issued and outstanding, respectively		21			21
Additional paid-in capital		20,037			18,277
Retained earnings		98,255			105,488
Total shareholders' equity		118,322			123,795
Total liabilities and shareholders' equity	$	180,737		$	164,117

PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except for per share amounts) (Unaudited)
		Three Months EndedJune 30,
		2023				2022
Sales		$	78,244			$	70,187
Cost of sales			55,718				50,244
Gross profit			22,526				19,943
Operating expenses:
General and administrative			15,711				9,351
Advertising			7,265				6,349
Depreciation and amortization			1,678				753
Total operating expenses			24,654				16,453
(Loss) income from operations			(2,128	)			3,490
Other income:
Interest income, net			620				117
Other, net			506				198
Total other income			1,126				315
(Loss) income before (benefit) provision for income taxes			(1,002	)			3,805
(Benefit) provision for income taxes			(115	)			1,030
Net (loss) income		$	(887	)		$	2,775
Net (loss) income per common share:
Basic		$	(0.04	)		$	0.14
Diluted		$	(0.04	)		$	0.14
Weighted average number of common shares outstanding:
Basic			20,333				20,208
Diluted			20,333				20,291
Cash dividends declared per common share		$	0.30			$	0.30

PETMED EXPRESS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands) (Unaudited)
	Three Months EndedJune 30,
	2023				2022
Cash flows from operating activities:
Net (loss) income	$	(887	)		$	2,775
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		1,678				753
Share based compensation		1,760				1,536
Deferred income taxes		(450	)			(294	)
Bad debt expense		19				45
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable		(46	)			86
Inventories - finished goods		(10,185	)			9,880
Prepaid income taxes		335				681
Prepaid expenses and other current assets		(2,390	)			451
Operating lease right-of-use assets, net		196				–
Accounts payable		9,115				(10,469	)
Accrued expenses and other current liabilities		1,369				97
Lease liabilities		(205	)			–
Deferred revenue		253				–
Income taxes payable		–				839
Net cash provided by operating activities	$	562			$	6,380
Cash flows from investing activities:
Purchase of minority interest investment in Vetster		–				(5,000	)
Acquisition of PetCareRx, net of cash acquired		(35,859	)			–
Purchases of property and equipment		(1,153	)			(982	)
Net cash used in investing activities	$	(37,012	)		$	(5,982	)
Cash flows from financing activities:
Dividends paid		(6,102	)			(6,064	)
Net cash used in financing activities	$	(6,102	)		$	(6,064	)
Net decrease in cash and cash equivalents		(42,552	)			(5,666	)
Cash and cash equivalents, at beginning of period		104,086				111,080
Cash and cash equivalents, at end of period	$	61,534			$	105,414
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	–			$	–
Dividends payable in accrued expenses	$	1,507			$	791

Non-GAAP Financial Measures

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

• Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
• Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
• Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
• Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
• Adjusted EBITDA does not reflect certain expenses including the estimated state sales tax accrual which reduces cash available to us.
• Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA for each of the periods indicated:

Reconciliation of Non-GAAP MeasuresPetMed Express, Inc.(Unaudited)
	Three Months Ended
($ in thousands, except percentages)	June 30,2023				June 30,2022				$Change				%Change
Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:
Net (loss) income	$	(887	)		$	2,775			$	(3,662	)		(132	)%
Add (subtract):
Share-based Compensation	$	1,760			$	1,536			$	224			15	%
Income Taxes	$	(115	)		$	1,030			$	(1,145	)		(111	)%
Depreciation and Amortization	$	1,678			$	753			$	925			123	%
Interest (Income)/Expense	$	(620	)		$	(117	)		$	(503	)		430	%
Acquisition/Partnership Transactions and Other Items	$	1,126			$	355			$	771			n/m
Employee Severance	$	393			$	–			$	393			n/m
Adjusted EBITDA	$	3,335			$	6,332			$	(2,997	)		(47	)%

____________________1 Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.